HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission

PLoS Medicine

Volumn 11, Issue 4, 2014, Pages

  Voronin, Yegor ^a   Mofenson, Lynne M ^b   Cunningham, Coleen K ^c   Fowler, Mary G ^d   Kaleebu, Pontiano ^e   McFarland, Elizabeth J ^f   Safrit, Jeffrey T ^g   Graham, Barney S ^h   Snow, William ^a  

^a Global HIV Vaccine Enterprise   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VRC 01 ANTIBODY; MONOCLONAL ANTIBODY;

ARGENTINE HEMORRHAGIC FEVER; ARTICLE; BREAST FEEDING; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN LIGHT CHAIN GENE; MEASLES; MOTHER TO CHILD HIV TRANSMISSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLIOMYELITIS; RABIES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS TRANSMISSION; ADULT; BLOOD; CHILD; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; INFANT; MALE; MOTHER; NEWBORN; TRANSMISSION; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOTHERS;

EID: 84900389177     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001616     Document Type: Article

References (36)

1. UNAIDS (n.d.) Believe it. Do it-The Global Plan. Available: http://www.unaids.org/believeitdoit/the-global-plan.html. Accessed 8 August 2013.
2. UNAIDS (2013) 2013 progress report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive.
3. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149 doi:10.1073/pnas.0630530100.
4. Rollins N, Coovadia HM, (2013) Breastfeeding and HIV transmission in the developing world: past, present, future. Curr Opin HIV AIDS 8: 466-472 doi:10.1097/COH.0b013e3283632ba2.
5. Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, et al. (2011) Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 58: 224-228 doi:10.1097/QAI.0b013e318229147e.
6. Mofenson LM, (2010) Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 15: 537-553 doi:10.3851/IMP1574.
7. Ngarina M, Popenoe R, Kilewo C, Biberfeld G, Ekstrom AM, (2013) Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health 13: 1-9 doi:10.1186/1471-2458-13-450.
8. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, et al. (2012) Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 26: 2039-2052 doi:10.1097/QAD.0b013e328359590f.
9. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329: 112-124 doi:10.1016/j.jim.2007.09.017.
10. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412 doi:10.1038/nature11544.
11. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 doi:10.1126/science.1178746.
12. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470 doi:10.1038/nature10373.
13. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861 doi:10.1126/science.1187659.
14. Mascola JR, Haynes BF, (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225-244 doi:10.1111/imr.12075.
15. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199-1204 doi:10.1126/science.1241144.
16. Adler SP, Nigro G, (2013) Prevention of maternal-fetal transmission of cytomegalovirus. Clin Infect Dis Off Publ Infect Dis Soc Am 57 Suppl 4: S189-192 doi:10.1093/cid/cit585.
17. Centers for Disease Control (CDC) (1984) Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep 33: 285-290.
18. Centers for Disease Control and Prevention (CDC) (2012) FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 61: 212.
19. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537.
20. Migone T-S, Subramanian GM, Zhong J, Healey LM, Corey A, et al. (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361: 135-144 doi:10.1056/NEJMoa0810603.
21. Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, et al. (2011) Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 58: 399-407 doi:10.1097/QAI.0b013e31822f8914.
22. Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, et al. (1999) Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 179: 567-575 doi:10.1086/314637.
23. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109: 18921-18925 doi:10.1073/pnas.1214785109.
24. Global HIV Vaccine Enterprise (n.d.) HIV prevention trials in infants. Available: http://www.vaccineenterprise.org/content/prevention-trials-infants. Accessed 9 August 2013.
25. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, et al. (2010) Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362: 2271-2281 doi:10.1056/NEJMoa0911486.
26. Kesho Bora Study Group, de Vincenzi I (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171-180 doi:10.1016/S1473-3099(10)70288-7.
27. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, et al. (2011) Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 8: e1001015 doi:10.1371/journal.pmed.1001015.
28. Wadman M, (2013) HIV trial under scrutiny. Nature 493: 279-280 doi:10.1038/493279a.
29. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, et al. (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157-159 doi:10.1038/nbt.1601.
30. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817 doi:10.1126/science.1192819.
31. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711 doi:10.1038/31514.
32. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659 doi:10.1038/31405.
33. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737 doi:10.1038/nature05580.
34. WHO (2003) Antenatal care in developing countries. Available: http://www.who.int/maternal_child_adolescent/documents/9241590947/en/. Accessed 9 December 2013.
35. Centers for Disease Control and Prevention (CDC) (2011) FastStats: Births and natality. Available: http://www.cdc.gov/nchs/fastats/births.htm. Accessed 9 December 2013.
36. Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M, et al. (2013) Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 27: 337-346.